GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » E10

HLTRF (HLS Therapeutics) E10 : $-0.65 (As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

HLS Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.150. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.65 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was -54.20% per year. During the past 5 years, the average E10 Growth Rate was -83.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of HLS Therapeutics was 36.30% per year. The lowest was -126.80% per year. And the median was -9.10% per year.

As of today (2025-03-14), HLS Therapeutics's current stock price is $2.7325. HLS Therapeutics's E10 for the quarter that ended in Sep. 2024 was $-0.65. HLS Therapeutics's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of HLS Therapeutics was 692.50. The lowest was 6.03. And the median was 7.08.


HLS Therapeutics E10 Historical Data

The historical data trend for HLS Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics E10 Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 -0.16 -0.27 -0.42 -0.75

HLS Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.56 -0.75 -0.65 -0.64 -0.65

Competitive Comparison of HLS Therapeutics's E10

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Shiller PE Ratio falls into.



HLS Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, HLS Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.15/127.2847*127.2847
=-0.150

Current CPI (Sep. 2024) = 127.2847.

HLS Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 0.260 98.367 0.336
201503 -0.063 99.789 -0.080
201506 -0.003 100.500 -0.004
201509 -0.015 100.421 -0.019
201512 -0.019 99.947 -0.024
201603 -0.023 101.054 -0.029
201606 -0.015 102.002 -0.019
201609 -0.008 101.765 -0.010
201612 -1.103 101.449 -1.384
201703 -0.022 102.634 -0.027
201706 -0.015 103.029 -0.019
201709 -0.024 103.345 -0.030
201712 -0.403 103.345 -0.496
201803 -0.190 105.004 -0.230
201806 -0.020 105.557 -0.024
201809 -0.720 105.636 -0.868
201812 0.020 105.399 0.024
201903 -0.140 106.979 -0.167
201906 -0.060 107.690 -0.071
201909 -0.060 107.611 -0.071
201912 -0.420 107.769 -0.496
202003 0.004 107.927 0.005
202006 -0.200 108.401 -0.235
202009 -0.050 108.164 -0.059
202012 -0.230 108.559 -0.270
202103 -0.150 110.298 -0.173
202106 -0.070 111.720 -0.080
202109 -0.060 112.905 -0.068
202112 -0.130 113.774 -0.145
202203 -0.110 117.646 -0.119
202206 -0.280 120.806 -0.295
202209 -0.140 120.648 -0.148
202212 -0.200 120.964 -0.210
202303 -0.180 122.702 -0.187
202306 -0.290 124.203 -0.297
202309 -0.210 125.230 -0.213
202312 -0.170 125.072 -0.173
202403 -0.190 126.258 -0.192
202406 -0.180 127.522 -0.180
202409 -0.150 127.285 -0.150

Add all the adjusted EPS together and divide 10 will get our e10.


HLS Therapeutics  (OTCPK:HLTRF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of HLS Therapeutics was 692.50. The lowest was 6.03. And the median was 7.08.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


HLS Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.